PetIQ Inc (NASDAQ:PETQ) CFO John Newland sold 11,000 shares of the firm’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $31.65, for a total value of $348,150.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.
John Newland also recently made the following trade(s):
On Monday, September 17th, John Newland sold 5,500 shares of PetIQ stock. The shares were sold at an average price of $40.76, for a total value of $224,180.00.
PETQ stock traded down $0.18 during midday trading on Thursday, hitting $31.43. 615,100 shares of the company’s stock were exchanged, compared to its average volume of 507,296. The company has a quick ratio of 1.10, a current ratio of 2.51 and a debt-to-equity ratio of 0.49. PetIQ Inc has a 12-month low of $17.56 and a 12-month high of $43.93. The company has a market capitalization of $890.30 million, a PE ratio of 80.59, a P/E/G ratio of 1.67 and a beta of 1.52.
PetIQ (NASDAQ:PETQ) last posted its quarterly earnings data on Tuesday, November 13th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.22. PetIQ had a positive return on equity of 11.68% and a negative net margin of 0.12%. The company had revenue of $131.40 million for the quarter, compared to the consensus estimate of $125.22 million. During the same period in the previous year, the business earned $0.30 EPS. PetIQ’s revenue for the quarter was up 116.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that PetIQ Inc will post 0.76 EPS for the current year.
PETQ has been the topic of several analyst reports. SunTrust Banks lifted their price objective on PetIQ to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 15th. Jefferies Financial Group restated a “buy” rating on shares of PetIQ in a report on Friday, August 24th. Raymond James restated a “buy” rating and set a $45.00 price objective (up from $33.00) on shares of PetIQ in a report on Wednesday, September 19th. CL King initiated coverage on PetIQ in a report on Friday, September 28th. They set a “buy” rating and a $49.00 price objective on the stock. Finally, Oppenheimer lifted their price objective on PetIQ from $28.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, October 5th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $41.83.
Hedge funds have recently bought and sold shares of the business. Harvest Fund Management Co. Ltd acquired a new position in shares of PetIQ in the 3rd quarter worth approximately $135,000. Zions Bancorporation acquired a new position in shares of PetIQ in the 3rd quarter worth approximately $187,000. Advisory Services Network LLC grew its position in shares of PetIQ by 296.0% in the 3rd quarter. Advisory Services Network LLC now owns 4,950 shares of the company’s stock worth $195,000 after acquiring an additional 3,700 shares in the last quarter. Engineers Gate Manager LP acquired a new position in shares of PetIQ in the 3rd quarter worth approximately $200,000. Finally, Cim LLC acquired a new position in shares of PetIQ in the 3rd quarter worth approximately $204,000. Institutional investors own 78.45% of the company’s stock.
PetIQ Company Profile
PetIQ, Inc operates as a pet health and wellness company. It provides veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats. The company offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.
Featured Article: How to read a candlestick chart